{"id":46573,"date":"2022-07-26T14:02:01","date_gmt":"2022-07-26T12:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/"},"modified":"2022-07-26T14:02:01","modified_gmt":"2022-07-26T12:02:01","slug":"affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/","title":{"rendered":"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer"},"content":{"rendered":"
\n

\nDr. Nagorsen brings over two decades of leadership in oncology, most recently at Amgen where he led the early development of<\/i> Lumakras\u00ae<\/sup> and Blincyto\u00ae<\/sup><\/i>\n<\/p>\n

BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc<\/a>., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Dirk Nagorsen, M.D., as the company\u2019s Chief Medical Officer. Dr. Nagorsen previously served as Vice President Early Development and Therapeutic Area Head, Hematology & Oncology Early Development at Amgen, where he oversaw multiple groundbreaking programs including the first approved KRAS targeted treatment, Lumakras\u00ae (sotorasib) and multiple T cell-based agents.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are seeing rapid advances in both cell therapy and our ability to target oncogenic driver mutations commonly found in hard-to-treat solid tumors,” said Dr. Nagorsen. \u201cBy combining the potency of T cells with synthetic biology and the specificity of T cell receptors, Affini-T\u2019s team of world-class researchers and drug developers can fully realize the potential of oncogenic driver mutations as the solution to potentially cure patients with solid tumors. With this, I see the company at the forefront of a new chapter in precision immunotherapy, and I am proud to join as Chief Medical Officer.\u201d\n<\/p>\n

\n\u201cHaving overseen development of the first approved KRAS targeting agent, Dirk\u2019s pioneering work in the space and passion for discovering new cancer treatments will fuel Affini-T\u2019s development of novel therapies for intractable solid tumors with oncogenic driver mutations,\u201d said Arjun Goyal, M.D., M.Phil., Co-founder and Managing Director Vida Ventures and Co-founder of Affini-T. \u201cWe look forward to Dirk\u2019s leadership and contributions as we work together to efficiently advance Affini-T\u2019s development strategy and bring impactful medicines to patients globally.\u201d\n<\/p>\n

\nDr. Nagorsen has contributed more than 20 years to the hematology and oncology fields, both in academia and industry. During the course of his 10 plus years at Amgen, he oversaw more than 30 oncology programs spanning from IND filings through drug approvals. He also served as the Global Development Leader for Blincyto\u00ae (blinatumomab), the first CD3 bispecific T cell engager targeting CD19, and led his team to secure Amgen\u2019s first breakthrough designation and first accelerated approval in 2014. Before joining Amgen, he served as a Senior Medical Director at Micromet, a German biotech, through its acquisition by Amgen in 2012. Dr. Nagorsen\u2019s groundbreaking research has resulted in over 60 peer-reviewed manuscripts, including papers published in New England Journal of Medicine, Journal of Clinical Oncology and Lancet Oncology. Dr. Nagorsen earned his medical doctorate and his habilitation (second scientific degree, equivalent of a Ph.D.) in experimental medicine and tumor immunology from Charit\u00e9 University Medicine Berlin. He trained in internal medicine, hematology and oncology at the Free University Berlin Medical School, at the NIH Clinical Center Bethesda, Maryland and at Charit\u00e9 University Medicine Berlin.\n<\/p>\n

\n\u201cDirk played a foundational role in the development of the first KRAS-targeted therapy that not only received FDA approval but did so within three years of the start of its Phase I trial,\u201d said Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, Affini-T Therapeutics. \u201cAs we look to leverage our platform to make a meaningful impact for patients with solid tumors, we believe that Dirk is uniquely positioned to drive the development of our clinical programs. We are delighted to have Dirk join our team and look forward to advancing potentially curative therapies.”\n<\/p>\n

\nAbout Affini-T Therapeutics<\/b>\n<\/p>\n

\nAffini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts<\/b>
Danielle Cantey
\n
Evoke Canale
\n
Danielle.Cantey@evokegroup.com<\/a>
619-826-4657\n<\/p>\n

\nIan Stone
\n
Evoke Canale
\n
Ian.stone@evokegroup.com<\/a>
619-849-5388\n<\/p>\n

\nInvestor Contact<\/b>
IR@affinittx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Dr. Nagorsen brings over two decades of leadership in oncology, most recently at Amgen where he led the early development of Lumakras\u00ae and Blincyto\u00ae BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Dirk Nagorsen, M.D., as the company\u2019s Chief … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46573","6":"format-standard","7":"category-industry"},"yoast_head":"\nAffini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Dr. Nagorsen brings over two decades of leadership in oncology, most recently at Amgen where he led the early development of Lumakras\u00ae and Blincyto\u00ae BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Dirk Nagorsen, M.D., as the company\u2019s Chief ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-26T12:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220726005375\/en\/1524342\/21\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer\",\"datePublished\":\"2022-07-26T12:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/\"},\"wordCount\":706,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005375\\\/en\\\/1524342\\\/21\\\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/\",\"name\":\"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005375\\\/en\\\/1524342\\\/21\\\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg\",\"datePublished\":\"2022-07-26T12:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005375\\\/en\\\/1524342\\\/21\\\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005375\\\/en\\\/1524342\\\/21\\\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer - Pharma Trend","og_description":"Dr. Nagorsen brings over two decades of leadership in oncology, most recently at Amgen where he led the early development of Lumakras\u00ae and Blincyto\u00ae BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Dirk Nagorsen, M.D., as the company\u2019s Chief ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-26T12:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220726005375\/en\/1524342\/21\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer","datePublished":"2022-07-26T12:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/"},"wordCount":706,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220726005375\/en\/1524342\/21\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/","url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/","name":"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220726005375\/en\/1524342\/21\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg","datePublished":"2022-07-26T12:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220726005375\/en\/1524342\/21\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220726005375\/en\/1524342\/21\/Dirk_Nagorsen_Headshot_Open_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46573"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46573\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}